WHAT IS CLAIMED IS:

1. Use of a cyanobacterial biomass in the manufacture of a medicament or a nutraceutical composition for use in the treatment of HBV infection in a subject in need thereof by reducing the level of hepatitis B surface antigen (HBsAg) detectable in the subject, wherein the cyanobacterial biomass is derived from *Arthrospira maxima*.

2. The use according to claim 1, wherein the subject suffers from chronic HBV infection.

3. The use according to claim 1, wherein the subject suffers from insomnia associated with chronic HBV infection.

4. The use according to claim 1, wherein the subject suffers from liver fibrosis associated with chronic HBV infection.

5. The use according to claim 1, wherein the cyanobacterial biomass is used in a combination therapy, which comprises an antiviral agent.

6. The use according to claim 1, wherein the cyanobacterial biomass is formulated in a pharmaceutical composition, which comprises an effective amount of the cyanobacterial biomass and a pharmaceutically acceptable excipient.

7. The use according to claim 6, wherein the pharmaceutical composition is formulated into a solid dosage form.

8. The use according to claim 7, wherein the pharmaceutically acceptable excipient is silicon dioxide or a sucrose ester of fatty acid.

9. The use according to claim 6, wherein the effective amount is 1 to 1,000 mg/Kg body weight per day.

10. The use according to claim 9, wherein the effective amount is 20-200 mg/Kg body weight per day.

11. The use according to claim 6, wherein the effective amount is 1 to 20 grams per day.

12. The use according to claim 1, wherein the cyanobacterial biomass is administered daily for at least one month.

13. The use according to claim 1, wherein the cyanobacterial biomass is administered orally.